Research programme: synthetic hepatitis B DNA vaccine - Aldevron/CytoGenix

Drug Profile

Research programme: synthetic hepatitis B DNA vaccine - Aldevron/CytoGenix

Alternative Names: Synthetic HBV DNA vaccine - Aldevron/ Cytogenix

Latest Information Update: 08 Jun 2010

Price : $50

At a glance

  • Originator Aldevron LLC; CytoGenix
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 01 Sep 2005 Preclinical trials in Hepatitis B in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top